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The role of type I interferons (IFNs) in SLE pathogenesis has been a subject of intense
investigation in the last decade. The strong link between type I IFNs and SLE was initially
provided by ex vivo studies showing that exposure of peripheral blood mononuclear cells
to immune complexes from SLE patients elicits a signature of IFN inducible genes and
was then further highlighted by human genetic studies. The mechanisms by which type I
IFNs, especially IFN alpha (IFNα), modulate the immune system and exacerbate SLE have
been largely elucidated through studies in mouse lupus models. In this review, we discuss
the characteristics of several such models in which disease is accelerated by ectopically
expressed IFNα.We also summarize several studies which tested therapeutic interventions
in these models and discuss the advantages and disadvantages of using IFNα accelerated
models to study experimental treatments for lupus.
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INTRODUCTION
In the last decade, type I interferons (IFNs) have received partic-
ular attention for their role in the pathogenesis of systemic lupus
erythematosus (SLE). The induction of anti-dsDNA antibodies
and development of lupus-like symptoms in a small number of
IFN treated patients with cancer or infectious diseases suggested
a causal link between this cytokine and SLE (1). The discovery of
the “IFNα signature,” which refers to the augmented expression
of a group of IFNα induced genes, in peripheral blood mononu-
clear cells (PBMCs) from active lupus patients further highlighted
the essential role of type I IFNs in the disease (2, 3). The IFN
signature is induced in healthy PBMCs by SLE plasma contain-
ing nucleic acid associated immune complexes and this induction
is inhibited by anti-IFNα antibody (4). Furthermore, polymor-
phisms in several genetic loci that are involved in the toll-like
receptor (TLR)/IFN signaling pathway are associated with SLE
risk (5, 6). These reports establish the important role of IFNα in
the pathogenesis of SLE and are the basis for the development of
drugs that target Type I IFNs or their receptor.
Type I IFNs are produced by several different cell types and
are of major importance in anti-viral defense. In conventional
dendritic cells, Type I IFN production is triggered by a several
mechanisms including activation of endosomal TLR3 and bind-
ing to cytosolic nucleic acid receptors [reviewed (7) – Table 1]. By
contrast, plasmacytoid dendritic cells (pDCs) are a major source
of Type I IFN in SLE. Opsonized apoptotic material or circulat-
ing immune complexes of self-nucleic acids and autoantibodies
are taken up by pDCS through the Fcγ receptor (8) and their
nucleic acid components can then traffic to the endosome where
they interact with TLR7 or TLR9. The adaptor molecule MyD88 is
then recruited and this results in phosphorylation of IRAK1 and
activation of the transcription factor IRF7 that induces IFN pro-
duction. pDCs rapidly produce large amounts of IFNs owing to
their constitutive expression of IRF7 (1, 9–11). Recent studies have
shown that cytosolic DExD/H-Box helicases can sense cytoplas-
mic DNA (12) and initiate type I IFN production in human pDCs
through the IRF7 pathway (13). The interaction between DNA and
TLR9 is facilitated by a nuclear DNA binding protein HMGB1 (14)
which is a component of neutrophil derived neutrophil extracel-
lular traps (NETs) released from dying neutrophils in SLE (15).
Other components of NETs protect nucleic acids from degrada-
tion and enhance their ability to form stable immune complexes
with SLE related autoantibodies (16).
Type I IFNs can be induced in conventional DCS and
macrophages following activation of TNFR1 and LTβR receptors.
In addition, intracytoplasmic nucleic acids may trigger cytoplas-
mic receptors and activate a mitochondrial membrane pathway
culminating in phosphorylation of IRF7 and Type I IFN produc-
tion [reviewed (7)]. A complete description of the molecular path-
ways involved in type I IFN production in SLE is beyond the scope
of this article but is the subject of several recent reviews (7, 17).
Type I IFNs have profound effects on the innate and adaptive
immune systems [reviewed (7, 17, 18) – Table 1]. Serum from
SLE patients induces monocytes from healthy donors to acquire a
DC-like phenotype and become potent activators of T cells (19)
in an IFNα dependent manner. Furthermore, IFNα acts on con-
ventional DCs to enhance their production of an important B
cell survival factor, B cell activating factor (BAFF) (20, 21). IFNα
upregulates TLR7 expression on B cells, which in turn mediates
increased expression of TACI, a receptor for BAFF (22). Its dual
role in promoting BAFF production of DCs and enhancing the
responsiveness of B cells to BAFF makes IFNα an important modu-
lator of the fate of autoreactive B cells. Furthermore, IFNα drives B
cell differentiation into CD138+ plasmablasts; terminal differen-
tiation into Ig-secreting plasma cells is mediated by IL-6, another
cytokine produced by activated pDCs (23). Finally, type I IFNs
stimulate CD4 T cells to enhance antigen-specific B cell responses
and prevent activated T cell death in mice (24, 25). These immuno-
logical features of type IFNs may all contribute to the pathogenesis
of SLE.
Direct evidence for the essential role of IFNs in SLE was
achieved through studies using lupus-prone mice that are
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Table 1 | Induction and pro-inflammatory effects of Type I interferons.
Cell type Effect Mechanisms Reference
B cells Induction of autoantibodies Enhancement of response to TLR activation (18, 35)
Upregulation of MHCII, CD86, CD69
Induction of germinal centers Increased class switch to pathogenic isotypes IgG2a and IgG3
Dysregulation of CD62L expression with increased shuttling of
antigen from the MZ to the follicles
Induction of plasma cells Enhanced crosstalk with IL-6 signaling
Induction of miR-15a and repression of PAX5
Increased expression of BLIMP and XBP
Induction of short-lived plasma cells Decreased bone marrow expression of CXCL12 and VCAM-1 (34)
Conventional
dendritic cells
Release of Type I IFN in response to TLR3
activation
TRAF3 mediated recruitment of TBK1, IKKε, and IRF3, leading to IRF3
phosphorylation
(7, 17)
Release of Type I IFNS through receptors
for cytosolic nucleic acids
RIG-I mediated recruitment of the MAVS adapter and mitochondrial
membrane assembly of a TRAF3, TBK1, and IKKε signalosome
leading to IRF3 phosphorylation
IFI16 mediated induction of a STING, TBK, IRF3-dependent pathway
Priming for antigen presentation Upregulation of MHC and costimulatory molecules
Increased expression of CCR7
Release of cytokines including BAFF TRAF6 mediated NFκB activation
Plasmacytoid
dendritic cells
Rapid release of high concentrations of
Type IFN in response to immune complexes
High levels of endosomal TLR7, 8, and 9 and activation of the MyD88
adaptor
Constitutive expression of IRF7
Formation of late endosomes
T cells CD4 T cell stimulation Increased IFNγ production (7, 24)
Enhanced survival
Priming for induction of CD8 killer cells Increased cross-presentation
Increased gene transcription
Enhanced responsiveness to IL-2 and IL-15
Decreased Treg function Downregulation of intracellular cAMP (62)
genetically deprived of type I IFN signaling or treated with
exogenous type I IFNs. Ifnar1 gene deficiency largely protects
lupus-prone mice from disease onset or attenuates disease severity
(26–29). Conversely, transient overexpression of exogenous IFNα
accelerates disease progression in all lupus-prone mice tested to
date. This makes these models not only useful tools to understand
the role of IFNs in SLE, but also useful platforms to test potential
therapies for SLE.
IFNα ACCELERATED LUPUS MOUSE MODELS
NZB/W F1 MICE
New Zealand black/New Zealand white (NZB/W) F1 mice are a
widely used animal model for lupus; they mimic human lupus
in several aspects including gender specificity, the appearance of
circulating anti-dsDNA antibodies, renal deposition of immune
complexes and the development of fatal glomerulonephritis. They
do not develop skin disease or hematologic manifestations and
thus have been used primarily to study SLE nephritis. NZB/W F1
mice develop proteinuria at a median age of 37 weeks and die by
the age of 1 year (30, 31). Although NZB/W F1 mice do not develop
detectable levels of circulating IFNα (20), the IFN signature can
be detected in splenic cells of pre-autoimmune NZB/W F1 mice
(32). The disease-initiating activities of IFNα in NZB/W F1 mice
were suggested by a report that treatment with poly IC, a TLR3
agonist, accelerates the disease in these mice (33). More recently,
a single injection of an adenovirus expressing IFNα (Ad-IFNα)
has been shown to accelerate the production of circulating anti-
dsDNA antibodies, renal deposition of immune complexes, onset
of proteinuria, and death in NZB/W mice in a dose dependent
manner (20, 34). The accelerated clinical manifestations are asso-
ciated with a vastly enhanced germinal center reaction, increased
serum levels of pro-inflammatory cytokines, and the induction of
T cell expression of IL-21 (34). This pro-inflammatory environ-
ment is associated with expanded B cells, CD4 T cells, and DCs
(34) and loss of B10 cells (35). Furthermore, IFNα virus injection
induces elevated serum levels of BAFF and increased TLR7 expres-
sion on splenic B cells (20–22, 34). Interestingly, although NZB/W
F1 mice normally possess a proportion of long-lived autoreac-
tive plasma cells in the spleen and BM, treatment with Ad-IFNα
skews the differentiation of autoreactive B cells almost completely
toward short-lived plasma cells [(34, 36) reviewed in (37)]. This
appears to be due to a decrease in bone marrow expression of
CXCL12 and VCAM-1, both of which are components of the bone
marrow plasma cell niche (34). Finally, in contrast to conventional
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mice, Ad-IFNα treated NZB/W F1 mice have far less renal intersti-
tial leukocyte infiltration. This is due to reduced renal expression
of pro-inflammatory chemokines such as CXCL13 and intrinsic
defects of leukocyte migration toward these chemokines (38).
Most of these features have also been reported in Ad-IFNα
treated New Zealand Mixed 2328 mice (39). However, despite a
large increase in T cell numbers, these mice do not develop a
preferential expansion of memory T cells following IFN treat-
ment or substantial glomerular macrophage infiltration as they
age, suggesting these two features may not be driven by type I
IFNs. In addition to the immune effects of Type I IFNs in this
model, administration of Ad-IFNα has a detrimental effect on
the vasculature, causing impairment of endothelium-dependent
vasorelaxation, a decrease in maturation of endothelial progeni-
tor cells into mature endothelial cells, increased platelet activation,
and accelerated thrombus formation, suggesting a potential role
for IFN in the accelerated atherosclerosis associated with SLE
(40).
Studies using cell depletion or mice with genetic deficiencies
have shown that disease acceleration by IFN is dependent on T
cells (NZB/W mice) (34), B cells (NZM2328 mice) and BAFF
(NZM2328 mice) (39).
NZW/BXSB MICE
Male NZW/BXSB mice carry two active copies of the TLR7 gene.
They develop anti-RNA and anti-phospholipid autoantibodies,
severe inflammatory nephritis and anti-phospholipid syndrome
with thrombocytopenia, myocardial infarcts, and cardiomyopathy
(41, 42). The survival of these mice is prolonged by prophylac-
tic treatment with anti-IFNAR antibody, suggesting the disease
process is driven by IFNα (43). In contrast, female mice with a
single active copy of TLR7 develop late onset nephritis, but not
anti-phospholipid syndrome (42, 44). Administration of Ad-IFNα
induced high titers of circulating anti-phospholipid, anti-Sm/RNP,
and anti-DNA autoantibodies and markedly accelerated nephri-
tis and death, but not anti-phospholipid syndrome in female
NZW/BXSB mice (44). These IFNα induced effects were accompa-
nied by a striking increase in activated B and T cells in the spleen.
Using female NZW/BXSB mice bearing the site-directed anti-
cardiolipin/DNA autoantibody VH transgene 3H9, IFNα has been
shown to relax the stringency for selection against autoreactivity
of the antigen selected B cell repertoire (45).
B6.SLe123
B6.Sle123 mice, that possess three SLE susceptibility loci, sponta-
neously develop highly penetrant severe systemic autoimmunity
and fatal glomerulonephritis beginning at 6 months of age. Young
pre-autoimmune mice that were treated with IFNα quickly devel-
oped renal immune complex deposition and nephritis, accompa-
nied by increased serum levels of pro-inflammatory cytokines such
as TNFα and IL-6, activation of DCs, B cells, and T cells, as well
as an enhanced germinal center response (46). As in the strains
discussed above, renal leukocyte infiltration was not affected by
IFNα treatment.
Collectively, these studies show that excess IFNα accelerates
progression of glomerulonephritis in most lupus models. The
acceleration and severity of the disease is dose dependent, allow-
ing researchers to control of the duration of their study. IFNα
induces a T dependent and enhanced germinal center response and
exhibits characteristics of the disease in the conventional strain.
For instance, IFNα induces anti-dsDNA antibodies in NZB/W F1
mice and anti-RNA antibodies in BXSB mice, these being the pre-
dominant specificities in the respective strains (20, 34, 44). Of
interest is the skewing of the antibody response from long-lived to
short-lived plasma cells in the NZB/W model, a feature associated
with alterations of the bone marrow environment. However, IFN
acceleration is associated with less renal inflammatory cell infil-
tration compared to its spontaneous counterpart. This is probably
due to the short disease course which does not allow these features
to develop to the same extent as in the conventional mice. It is
also important to note that other major manifestations of human
SLE including skin, hematologic, and neurologic disease cannot
be addressed using these models.
IFNλ ACCELERATION OF SLE
IFNλ is a family of Type III IFNs that mediate their biologic
activities through a receptor that is expressed predominantly on
epithelial cells and induce a similar pattern of gene expression as
Type I IFNs (47). Treatment of NZB/W mice with a continuous
infusion of IFNλ did not exacerbate disease, however the addition
of IFNλ to a low dose of IFNα modestly accelerated proteinuria
onset (35).
ASSOCIATION OF TYPE I IFNs WITH ALTERATION IN miRNAs
Type I IFN production can be regulated by miRNAs. For example,
underexpression of miR-146a was found to correlate with dis-
ease activity and with an IFN signature. miR-146a targets multiple
components of the IFN signaling pathway such that its deficiency
results in overexpression of IFN inducible genes. Importantly,
administration of TLR agonists or of Type I IFN induced expres-
sion of miR-146a indicating a physiologic feedback loop that
may be dysregulated in SLE (48). Delivery of miR-146a to lupus
PBMCs in vitro reduced the expression of IFN inducible genes (48)
and delivery to lupus-prone BXSB mice in vivo reduced the pro-
duction of pro-inflammatory cytokines and autoantibodies (49).
Thus miR-146a reduction is a biomarker for disease activity and
a potential therapeutic target. Another interesting observation in
the NZB/W model is the IFN induced expression of miR-15a in
the spleens of treated mice; this is associated with downregulation
of PAX5 and the emergence of autoantibodies and plasma cells.
Since PAX5 is a negative regulator of miR-15a, the upregulation of
miR-15a may be an early biomarker for IFN induction of plasma
cells (35).
USING THE IFNα ACCELERATED LUPUS MODEL TO TEST
THERAPEUTICS FOR SLE NEPHRITIS
IFNα KINOID
IFNα kinoid is an IFNα derived immunogen that triggers a strong
but transient production of neutralizing antibody against IFNα
(50). In a proof of principle experiment, prophylactic administra-
tion of kinoid delayed IFNα induced immune complex formation,
proteinuria, and death in NZB/W F1 mice (50). It is worth not-
ing that not all kinoid immunized mice mounted a substantial
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humoral response to IFNα and only the ones with antibody levels
above a certain threshold showed delayed clinical manifestations.
Moreover, a sustainable protective effect required prolonged pro-
duction of anti-IFNα antibody, suggesting that periodic booster
injections might be required to achieve a long-term antibody
dependent clinical benefit. The success of this study led to the
development of a human IFNα kinoid that induces antibodies
neutralizing all 13 subtypes of human IFNαs (51). This kinoid
has been shown to reduce the IFNα signature in lupus patients
(52).
BIOLOGIC THERAPIES
TACI-Ig is a fusion protein that inhibits the BAFF/APRIL sig-
naling pathway. The treatment of pre-autoimmune NZB/W F1
mice with TACI-Ig significantly delayed proteinuria onset and
substantially prolonged the survival of the mice (53). TACI-Ig
treatment achieved a similar clinical outcome in IFNα induced
NZB/W F1 mice, although the survival benefit was only apparent
when the treatment was started concomitant with IFN adminis-
tration and was no longer effective if it was delayed until autoan-
tibodies emerged (54). TACI-Ig treatment did not affect germinal
center formation, autoantibody production, renal deposition of
immune complexes, or pro-inflammatory cytokine expression in
lymphoid organs however it was associated with a decrease in
renal inflammation, prevention of activation of resident renal
macrophages, and a decrease in renal and serum levels of TNF
(54).
CTLA4-Ig, a drug that interrupts CD28-B7 interactions, pre-
vents disease onset in NZB/W F1 mice (55, 56). In contrast,
CTLA4-Ig at standard-dose failed to prevent or delay the onset
of nephritis in Ad-IFNα treated mice despite preventing T and B
cell activation, GC formation, and the production of pathogenic
IgG2a anti-dsDNA antibodies (54). Resistance to standard-dose
CTLA4-Ig was associated with the persistence of pathogenic IgG3
autoantibodies that were attenuated only after administration of
high-dose CTLA4-Ig. Although the mice treated with high-dose
CTLA4-Ig eventually died of nephritis, this treatment markedly
delayed proteinuria onset and protected the mice from interstitial
inflammation.
Ad-IFNα treatment in NZB/W F1 mice results in elevated
renal expression and increased serum levels of TNFα concomi-
tant with the onset of nephritis, making these mice an ideal model
to study the efficacy of TNF receptor 2 (TNFR2)-Ig (57). TNFR2-
Ig treatment delayed the onset of nephritis and prolonged survival
of IFN accelerated mice without affecting autoantibody produc-
tion or systemic immune activation. Similar to the observations
with TACI-Ig, the therapeutic effect of TNFR2-Ig was achieved
through inhibiting the renal response to immune complex depo-
sition. The upregulation of a panel of chemokines in response
to renal immune complex deposition was blocked by TNFR2-Ig
treatment, resulting in diminished recruitment of periglomerular
and interstitial F4/80hi macrophages. In addition, renal endothe-
lial cell activation and oxidative stress were decreased in the mice
treated with TNFR2-Ig.
CD137 (4-1BB) is an inducible T cell costimulatory receptor
belonging to the TNF receptor superfamily. It is expressed on
activated CD4 and CD8 T cells, and promotes the proliferation
of these cells. Treatment of NZB/W F1 mice with an agonistic
anti-CD137 antibody significantly delays the onset of nephritis
and prolongs survival (58). The therapeutic benefit is associated
with inhibition of IgG but not IgM anti-dsDNA antibodies (58),
consistent with an effect of anti-CD137 on T cell dependent but
not T cell independent humoral responses (59). In preliminary
experiments, we have shown that anti-CD137 antibody treatment
of IFN induced NZB/W mice markedly delays the formation of
germinal centers and the development of IgG2a and IgG3, but not
IgM anti-dsDNA antibodies and greatly protects the kidneys from
glomerular and interstitial injury (unpublished data), similar to
the observations in NZB/W F1 mice that develop disease spon-
taneously. As with TACI-Ig, maximal benefit was achieved if the
anti-CD137 treatment was started within 1 week of administration
of Ad-IFNα.
REMISSION INDUCTION THERAPIES
Triple therapy with cyclophosphamide (CTX), anti-CD40L, and
CTLA4-Ig induces remission in a high percentage of NZB/W
F1 mice with established nephritis (60). A similar percentage of
Ad-IFNα treated mice entered remission after this therapy but
they relapsed rapidly (54). Mice treated with high-dose Ad-IFNα
relapsed faster than mice treated with low dose Ad-IFNα and
the latter relapsed faster than conventional NZB/W F1 mice (54,
60). Production of anti-dsDNA antibodies and glomerular depo-
sition of IgG immune complex in Ad-IFNα treated NZB/W F1
mice were markedly reduced (54) by triple therapy, consistent
with the observation that IFNα induces predominantly short-lived
plasma cells which are susceptible to cytotoxic reagents (34). Nev-
ertheless, in the high-dose IFN group, new autoreactive plasma
cells formed as soon as the triple therapy drugs dissipated from
the serum and this was associated with reaccumulation of renal
immune complexes and rapid disease relapse. This is in con-
trast to conventional NZB/W F1 mice whose renal deposition of
immune complexes was not reversed by the triple therapy (60)
but whose renal response to immune complex deposition was
markedly attenuated.
THE UTILITY OF THE IFNα ACCELERATED LUPUS MODEL
Studies of therapeutic interventions in many strains of lupus-
prone mice, such as NZB/W mice, are hampered by the stochastic
disease onset and the length of time needed for the mice to
develop spontaneous disease. In contrast, IFNα induced disease
has a relatively synchronized onset and highly reproducible dis-
ease progression, allowing the study of therapies on defined stages
of disease including remission induction studies. In addition,
the IFNα induced model requires less time to develop clinical
manifestations and has a shorter window from disease onset to
death, allowing the therapies to be tested in a compact time
frame.
At the same time, one needs to be aware that Ad-IFNα treated
NZB/W F1 mice are not merely a hastened version of the spon-
taneous lupus model but they possess some distinct features. For
instance, Ad-IFNα treated NZB/W F1 mice almost completely lack
the long-lived plasma cells that exist in abundance in the spleen
and bone marrow of the conventional NZB/W F1 mice (34) and
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therefore may not be a suitable model to test therapies target-
ing these pathogenic cells. Similarly, the modest renal infiltration
with inflammatory cells renders the IFNα model less attractive
for studies focused on inhibitors of leukocyte trafficking. Finally
Ad-IFNα treatment also alters the response of disease to therapies
that are highly effective in the spontaneous disease. Such therapies
are for the most part only effective in the IFN model if they are
administered prophylactically. This may reflect a more dynamic
inflammatory environment in IFNα induced disease, rendering
the disease more resistant to therapeutic intervention. Whether
IFN signaturehi patients are similarly more resistant to drug inter-
ventions than IFN signaturelo patients needs to be determined
in the context of clinical trials. It is of interest in this regard
that preliminary studies of one anti-IFN agent showed no effect
on autoantibodies and demonstrated efficacy only in the IFN
signaturelo patient group (61, 63). By contrast, preliminary data
from a second trial of a different anti-IFN agent showed a trend
towards a better outcome in the patients with a high IFN signa-
ture (64). Further clinical trials are in progress. Overall Ad-IFNα
treated mice are a reliable but stringent model to test new therapies
for lupus nephritis. The difference in their response to therapies
may help to predict proper intervention for patients with an IFN
signature.
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